Recently published research has introduced FINAL (Fucoidan-docetaxel Immunomodulatory Nanoparticles as an Antitumoral Lancer), an innovative nanoplatform with the potential to address multiple cancer types. Read more
Marinova welcomes Meegan Grubb to the position of Analytical Chemist. Read more
In a new study, four commercial fucoidan extracts were independently characterised to determine their chemical composition, structural features and bioactivities. Read more
A new review paper explores the potential of fucoidan-based nanoparticles to support future colorectal cancer treatments. Read more
Marinova has seen a 33% increase in customers formulating with fucoidan for the functional food and beverage category. Read more